188797-80-0

Basic information

• Product Name: Ziprasidone Sulfoxide
• Synonyms: Ziprasidone Sulfoxide
• CAS NO: 188797-80-0
• Molecular Formula: C21H21ClN4O2S
• Molecular Weight: 428.93504
• Product Categories: Aromatics;Heterocycles;Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 188797-80-0.mol

Chemical Properties

• Melting Point: 145-148°C
• Appearance: /
• Density: 1.56±0.1 g/cm3(Predicted)
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated)
• PKA: 13.34±0.20(Predicted)
• CAS DataBase Reference: Ziprasidone Sulfoxide(CAS DataBase Reference)
• NIST Chemistry Reference: Ziprasidone Sulfoxide(188797-80-0)
• EPA Substance Registry System: Ziprasidone Sulfoxide(188797-80-0)

Safety Data

• Hazardous Substances Data: 188797-80-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ziprasidone Sulfoxide is used as a metabolite for the study and development of new antipsychotic drugs. Its unique chemical properties and potential therapeutic effects contribute to the advancement of mental health treatments.
Used in Research and Development:
Ziprasidone Sulfoxide is used as a research compound to investigate its potential applications and effects in various areas of pharmaceutical research. Its unique properties and metabolite status provide valuable insights into the development of new drugs and therapies.

Upstream product

• 122883-93-6 ziprazidone 

Relevant articles and documents

Stability-indicating spectrofluorimetric method for the assay of ziprasidone in capsules

A simple, rapid and highly sensitive spectrofluorimetric method was developed for determination of ziprasidone hydrochloride (ZPS) in capsules. The method is based on measuring the native fluorescence of ZPS in acetate buffer of pH 4.5 at 398 nm after excitation at 315 nm. The fluorescence-concentration plot was rectilinear over the range of 0.05-0.80 μg mL-1 with a lower detection limit (LOD) of 6.0 ng mL-1 and quantification limit (LOQ) of 20.0 ng mL-1. The method was fully validated and successfully applied to the determination of ZPS in its capsules with average percentage recovery of 99.7±1.4. The method was extended to stability study of ZPS. The drug was exposed to acidic, alkaline, oxidative and photolytic degradation according to ICH guidelines. Moreover, the method was utilized to investigate the kinetics of the alkaline, acidic and oxidative degradation of the drug. A proposal for the degradation pathways was postulated. Springer Science+Business Media, LLC 2009.

Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites

The invention relates to novel methods using, and pharmaceutical compositions comprising, ziprasidone metabolites. The methods and compositions of the invention are suitable for the treatment of neuroleptic and related disorders. The invention further encompasses methods of preparing ziprasidone sulfoxide and ziprasidone sulfone.